113. 筋ジストロフィー Muscular dystrophy Clinical trials / Disease details
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05747924 (ClinicalTrials.gov) | February 2023 | 17/2/2023 | Phase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) | A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | Facio-Scapulo-Humeral Dystrophy;Atrophy, Facioscapulohumeral;Atrophies, Facioscapulohumeral;Facioscapulohumeral Atrophy;Muscular Dystrophies;Muscular Dystrophy, Facioscapulohumeral;FSH Muscular Dystrophy;Landouzy Dejerine Dystrophy;Landouzy-Dejerine Muscular Dystrophy;Dystrophies, Landouzy-Dejerine;Dystrophy, Landouzy-Dejerine;Landouzy-Dejerine Syndrome;Muscular Dystrophy, Landouzy Dejerine;Progressive Muscular Dystrophy;FSH;Facioscapulohumeral Muscular Dystrophy 2;FSHD;FSHD1;FSHD2;FMD;FMD2;Fascioscapulohumeral Muscular Dystrophy;Fascioscapulohumeral Muscular Dystrophy Type 1;Fascioscapulohumeral Muscular Dystrophy Type 2;Dystrophies, Facioscapulohumeral Muscular;Dystrophy, Facioscapulohumeral Muscular;Facioscapulohumeral Muscular Dystrophy 1 | Drug: AOC 1020;Drug: Placebo | Avidity Biosciences, Inc. | NULL | Not yet recruiting | 18 Years | 65 Years | All | 72 | Phase 1/Phase 2 | NULL |